Display Settings:

Format

Send to:

Choose Destination
    Haematologica. 2002 Mar;87(3):306-19.

    Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity.

    Source

    Divisione di Ematologia, Ospedale A. Cardarelli, Naples, Italy. ferrara@itb.it

    Abstract

    BACKGROUND AND OBJECTIVES:

    Recent investigations in acute myeloid leukemia (AML) have clearly demonstrated that specific karyotypic abnormalities result in distinct biological and clinical entities. We focus on recent advances on biology and treatment of AML with t(8;21).

    DATA SOURCES AND METHODS:

    The information presented here derives from literature data and experience of the authors. The most relevant studies are critically analyzed and discussed.

    STATE OF ART:

    Peculiar molecular, morphologic, immunophenotypic and epidemiologic findings of AML with t(8;21) as well as current methods for the evaluation of minimal residual disease are presented. Results from current therapeutic options including consolidation chemotherapy or transplantation procedures are critically reviewed.

    PERSPECTIVES:

    Innovative therapeutic approaches based on risk-adapted, patient-oriented approaches would be possible in this AML subtype, provided that answers to many unresolved questions are given.

    PMID:
    11869944
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk